Slides
Page 1
Corporate Presentation September 2025
Page 2
Disclaimer This presentation has been prepared by Entrada Therapeutics, Inc. (the “Company”) and shall not constitute an offer to sell or a solicitation of an offer to buy securities or an invitation or inducement to engage in investment activity nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of such securities under the securities law of any such jurisdiction. The Company has filed a shelf registration statement (including a prospectus) with the Securities and Exchange Commission (the “SEC”) for the offering to which this presentation relates. Before you invest in any securities of the Company, you should read the prospectus in that registration statement and any other documents the Company has filed with the SEC for more complete information about the Company and the offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding the Company's strategy, future operations, prospects and plans, objectives of management, the validation and differentiation of the Company’s approach and EEV platform and its ability to provide a potential treatment for patients, expectations regarding the Company’s Phase 1/2 MAD clinical study of ENTR-601-44 in the U.K. and EU, including the release of data from the ELEVATE-44-201 study from the first patient cohort in the first half of 2026, expectations regarding the Company’s planned Phase 1/2 MAD clinical study of ENTR-601-45 in the U.K. and EU, including its initiation in the U.K. and EU and dosing of the first patient in the third quarter of 2025 and the release of initial data from the first patient cohort in mid-2026, the ability to recruit for and complete the ELEVATE-44-102 study in the U.S., including its initiation in the U.S. in the first half of 2026, the ability to recruit for and complete global Phase 2 clinical studies for ENTR -601-44, ENTR-601-45 and ENTR-601-50, expectations regarding the timing of global regulatory filings for the planned Phase 2 clinical studies for ENTR-601-50 in the fourth quarter of 2025 and for ENTR-601-51 in 2026, expectations regarding the timing of candidate nomination for a retinal disease program in 2025, the potential therapeutic benefits of the Company’s EEV product candidates and the ability to advance therapeutic candidates in indications beyond neuromuscular disease, including the potential for ENTR-601-44 to be a safe and transformative treatment option, the continued development and advancement of ENTR-601-44, -45, -50, and -51 for the potential treatment of DMD and the partnered product candidate VX-670 for the potential treatment of DM1, expectations regarding the anticipated contributions from recent key hires to the Company’s operations and progress, expectations regarding the progress and success of Entrada’s collaboration with Vertex, the ability to continue to expand and develop additional therapeutic programs, including further exon skipping programs, and the sufficiency of the Company’s cash resources into the second quarter of 2027, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate, ” “believe, ” “continue, ” “could, ” “estimate, ” “expect, ” “intend, ” “may, ” “might, ” “objective, ” “ongoing, ” “plan, ” “predict, ” “project, ” “potential, ” “should, ” or “would, ” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, int entions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candi dates, including the conduct of research activities and the initiation and completion of preclinical studies and clinical studies; uncertainties as to the availability and timing of results from preclinical and cli nical studies; the timing of and the Company’s ability to submit and obtain regulatory clearance and initiate clinical studies; whether results from preclinical studies or clinical studies will be predictive of the results of later preclinical studies and clinical studies; whether the Company's cash resources will be sufficient to fund the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in the Company's filings with the SEC, including the Company's most recent Form 10-K and in subsequent filings the Company may make with the SEC. In addition, the forward-looking statements included in this presentation represent the Company's views as of the date of this presentation. The Company anticipates that subsequent events and developments will cause its vie ws to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this presentation. September 2025 2
Page 3
OUR MISSION: To Treat Devastating Diseases With Intracellular Therapeutics September 2025 3 We’re proud to share the stories of JJ, Andrew, Max and Franklin – all living with Duchenne muscular dystrophy
Page 4
d Entrada is entering 2025 with momentumSignificant clinical momentum throughout 2025 Entrada expects to have four active clinical-stage programs by the end of 2025* ENTR-601-44: Currently dosing patients in UK and EU; Authorized in US ENTR-601-45: Patient study currently enrolling in UK and EU ENTR-601-50: On track to submit global regulatory filings in Q4 2025 MAD portion of VX-670 global Phase 1/2 to evaluate safety and efficacy is ongoing; Completion of enrollment and dosing expected in the H1 2026 Partnership terms include milestone payments, plus royalties Generating data from key preclinical programs, including ocular and metabolic diseases; Maturing platform investments in additional neuromuscular diseases Includes new moieties ~$354M cash balance Cash runway into Q2 2027 Rapidly expanding DMD franchise Vertex accelerating DM1 program Advancing preclinical pipeline Strong financial position** *All references in this presentation regarding planned regulatory filings and clinical study designs are subject to ongoing discussion with regulatory authorities; **Based on current operating plans and $354M in cash, cash equivalents and marketable securities as of June 30, 2025; MAD: Multiple ascending dose; DMD: Duchenne muscular dystrophy; DM1: Myotonic dystrophy type 1. September 2025 4
Page 5
Breakthrough approach to intracellular therapeutics September 2025 Increasing cellular uptake and improving endosomal escape We are leveraging our Endosomal Escape Vehicles (EEV ) and other technologies to optimize intracellular target engagement and therapeutic benefit 75% of disease- causing targets are located inside cells1 These targets are largely considered to be inaccessible and undruggable as only 2% of biological material will escape the endosome to reach an intracellular target2 Potential for best-in-class therapeutics Initial focus on neuromuscular with expansion into ocular and metabolic diseases, where we are working to develop safe and effective therapies that meet the significant needs of patients 1Verdine GL, Walensky LD. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin Cancer Res. 2007;13(24):7264-70; 2Kilchrist KV, et al. Gal8 visualization of endosome disruption predicts carrier-mediated biologic drug intracellular bioavailability. ACS Nano. 2019;13(2):1136-52. 5
Page 6
Endosomal Escape Vehicle (EEV )-based therapies September 2025 6 High Intracellular Uptake ~90% Uptake Efficient Endosomal Escape ~50% Escape vs. ~2% Standard Unique Budding Mechanism Conserves Endosomal Integrity Unique chemistry Improved uptake and endosomal escape Cyclic structure Extended half-life and increased stability Phospholipid binding Broad biodistribution to all cells Consistent and predictable pharmacokinetics Same EEV used across initial programs Qian, Z. et al. ACS Chem. Biol. 2013; Qian, Z. et al. Biochemistry 2014; Qian, Z. et al. Biochemistry 2016; Sahni, A. et al. ACS Chem. Biol. 2020; Pei, D. Acc. Chem. Res. 2022.
Page 7
d Entrada’s pipeline includes a diverse array of high potential and high value assets Each target disease has a substantial patient population with a significant unmet medical need An Expanding Pipeline of Intracellular Therapeutics September 2025 7 Discovery IND EnablingLead Optimization ENTR-601-50 ENTR-601-44 ENTR-601-45 ENTR-601-51 Duchenne Muscular Dystrophy (DMD) Clinical Development Pipeline Expansion Platform Expansion Undisclosed Programs Undisclosed Ocular Myotonic Dystrophy Type 1 (DM1) VX-670
Page 8
Entrada expects to have four clinical-stage programs by the end of 2025 EEV therapies have the potential for a best-in-class approach in neuromuscular diseases September 2025 8 Delivered positive Phase 1 data in DMD (ENTR-601-44) • Robust clinical validation in healthy volunteers • No treatment-related AEs • Potential best-in-class target exposure and target engagement • Potential for minimum of 6-week dosing intervals Strong, translational DMD data support franchise expansion • Leverages ENTR-601-44’s positive Phase 1 results • Best-in-class potential for ENTR-601-44, ENTR-601-45, ENTR-601-50 and ENTR-601-51 • Pursuing efficient, direct-to- patient clinical strategy Vertex partnership further validates EEV potential (VX-670) • Completed SAD portion of global Phase 1/2 clinical study • MAD portion of VX-670 global Phase 1/2 to evaluate safety and efficacy is ongoing • Completion of enrollment and dosing expected in H1 2026
Page 9
(n=6:2) (n=6:2) (n=6:2) (n=6:2) Positive ENTR-601-44 Phase 1 data support the initiation of a Phase 1/2 MAD clinical study in patients September 2025 *Data presented at 2024 World Muscle Society conference; **One participant enrolled and randomized into Cohort 3 was removed prior to dosing. 9 Cohort 1 0.75 mg/kg Cohort 2 1.5 mg/kg Cohort 3 3 mg/kg** Cohort 4 6 mg/kg 32 Adult Subjects Outcome Measures Key findings: Strong clinical safety up to 6 mg/kg, with the potential for best-in-class pharmacokinetics and pharmacodynamics in patients 6:2 randomization Single IV dose Total Active: Placebo = 24:8 • Safety and tolerability • Evaluation of PK and PD • Target engagement as measured via exon skipping ENTR-601-44-101: Placebo-controlled single ascending dose (SAD) study in healthy volunteers*
Page 10
ENTR-601-44-101: Safety Safety and tolerability were assessed at each study visit following a single IV dose of ENTR-601-44 or placebo; One participant enrolled and randomized into Cohort 3 was removed prior to dosing; Renal biomarkers assessed using FNIH and the C-Path; Kidney Safety CM Biomarker User’s Guide v1.1, 2019; AE: Adverse event; SAE: Serious adverse event; TEAE: Treatment-emergent adverse event. September 2025 10 ENTR-601-44-101: No treatment-related adverse events were reported in the ENTR-601-44- 101 study up to the highest dose of 6 mg/kg n (%) Pooled placebo (N=8) ENTR-601-44 0.75 mg/kg (n=6) 1.5 mg/kg (n=6) 3.0 mg/kg (n=7) 6.0 mg/kg (n=6) Total (N=25) Dosed 8 6 6 6 6 24 Completed Study 8 6 6 6 6 24 Any TEAE 1 5 2 3 3 13 Treatment- related TEAE 0 0 0 0 0 0 • No AEs related to study drug • Most common AE was headache (n=7; 5 mild and 2 moderate) • No clinically significant findings with lab values, ECG or vital signs • No adverse findings or clinically relevant changes to biomarkers of renal toxicity at highest dose of 6 mg/kg
Page 11
Plasma Concentration of ENTR-601-44 Dose-Dependent Increases in Urinary Excretion of Final PMO-44 Metabolite ENTR-601-44 Dose (mg/kg) Plasma ENTR-601-44 AUClast (hr*ng/mL) 0 30.75 1.5 6 0 20,000 40,000 60,000 11 For every doubling of dose, there is a more than doubling of metabolite excretion, implying the potential for increasing efficacy without a proportional risk of increasing toxicity High drug concentration supports potential for efficacy at relatively low doses September 2025 (Left) Blood samples for PK assessment were collected at 2 hours pre-dose and post-end of infusion: 5 minutes, 1 hour, 4 hours, 8 hours, 16 hours, 24 hours and every 24 hours after; Additional samples were taken at follow-up study visits; (Right) 24-hour urine samples for PK assessment were collected the day prior to dosing and every 24 hours after; Additional samples were taken at follow-up study visits; Data shown as mean ± standard deviation; AUClast: Area under the plasma concentration-time curve to the last measurable plasma concentration. ENTR-601-44-101: Potential best -in-class dose -dependent pharmacokinetics ENTR-601-44-101: Pharmacokinetics Increase (%) 100% 100% 100% 114% 130% 184% 0% 50% 100% 150% 200% 0.75 to 1.5 mg/kg 1.5 to 3 mg/kg 3 to 6 mg/kg ENTR-601-44 Dose Change (%) Metabolite Excretion Change (%)
Page 12
Muscle concentrations and exon skipping were assessed using a needle muscle biopsy taken from biceps brachii 72 hours (±4 hours) post-dose of ENTR-601-44; Box and whisker plot illustration: the boxes represent the IQR and median; Whiskers show the smallest and largest values within 1.5 times the IQR; **p<0.005 vs. placebo using Mann-Whitney U test; IQR: Interquartile range; LLOQ: Lower level of quantification. 0 20 10 50 40 30 70 60 80 Concentration of final metabolite (ng/g) 6 mg/kg ENTR-601-44 3 mg/kg ENTR-601-44 LLOQ 0.4 0.2 0.0 0.8 0.6 1.0 Exon 44 skipping (%) 6 mg/kg ENTR-601-44 ** Placebo LLOQ September 2025 12 Skeletal Muscle Concentration DMD Exon 44 Skipping Robust target engagement with statistically significant exon skipping observed versus placebo Dose-dependent skeletal muscle concentration was observed ENTR-601-44-101: Favorable target exposure and engagement at 6 mg/kg ENTR-601-44-101: Target exposure and engagement
Page 13
Rapidly expanding DMD clinical programs September 2025 13 ENTR-601-44’s Phase 1 results unlock DMD portfolio investment across multiple populations ENTR-601-44 ENTR-601-45 ENTR-601-51 ENTR-601-50 • Regulatory filings expected in Q4 2025 • Global Phase 1/2 MAD initiation expected in H1 2026 • Global Phase 1/2 MAD regulatory filings expected 2026 1Parent Project Muscular Dystrophy; 2European Medicines Agency: Orphan designation for treatment of Duchenne muscular dystrophy (EU/3/20/2375); FPD: First patient dosed. ~41,000 people in the US1 and Europe2 have Duchenne 44 45 50 51 14% 9% 8% 4% ENTR-601 ELEVATE-44-201: • Global Phase 1/2 MAD study in patients ongoing • Data from Cohort 1 expected H1 2026 ELEVATE-44-102: • Authorized for Phase 1b MAD study in patients • Study initiation expected H1 2026 ELEVATE-45-201: • Global Phase 1/2 MAD study initiated; FPD expected in Q3 2025 • Data from Cohort 1 expected mid-2026
Page 14
ENTR-601-44-201: MAD clinical study design 14 ELEVATE-44-201 is a global, two-part, randomized, double-blind placebo-controlled Phase 1/2 study in ambulatory patients with DMD who are exon 44 skipping amenable Accelerated Approval Regulatory Filings* Multiple Ascending Dose Phase 2b Collection of Safety and Biomarker Data Clinical Proof of Concept Study participants may be eligible to enter an open label extension study (OLE) *Phase 2b and potential for accelerated approval is subject to regulatory feedback.September 2025 PART A PART B FPD achieved; Cohort 1 data expected H1 2026 Part A Trial Design: • 3 MAD cohorts • Placebo controlled • ~24 ambulatory pediatric patients • Dosing interval every 6 weeks • Doses 6 mg/kg up to 18 mg/kg • Estimated 6-month duration Primary Objective • Safety and tolerability of ENTR-601-44 Secondary Objectives • Evaluation of pharmacokinetics • Evaluation of exon skipping and dystrophin production (skeletal muscle biopsy)
Page 15
ENTR-601-45-201: MAD clinical study design 15 Part A Trial Design: • 3 MAD cohorts • Placebo controlled • ~24 ambulatory pediatric patients • Dosing interval every 6 weeks • Doses 5 mg/kg up to 15 mg/kg • Estimated 6-month duration ELEVATE-45-201 is a global, two-part, randomized, double-blind placebo-controlled Phase 1/2 study in ambulatory patients with DMD who are exon 45 skipping amenable *Phase 2b and potential for accelerated approval is subject to regulatory feedback. September 2025 Primary Objective • Safety and tolerability of ENTR-601-45 Secondary Objectives • Evaluation of pharmacokinetics • Evaluation of exon skipping and dystrophin production (skeletal muscle biopsy) Accelerated Approval Regulatory Filings* Multiple Ascending Dose Phase 2b Collection of Safety and Biomarker Data Clinical Proof of Concept Study participants may be eligible to enter an open label extension study (OLE) PART A PART B FPD expected in Q3 2025; Cohort 1 data expected mid-2026
Page 16
Gene Editing RNA Splicing RNA Editing RNA Silencing RNA Blocking Protein Replacement Protein Degradation Protein Inhibition Pipeline expansion opportunities Deliver CRISPR enzyme and repair gene function with guide RNA Deliver oligonucleotide therapeutics for RNA editing Modify RNA via exon/intron splicing to activate protein expression Block trinucleotide repeats in RNA to inhibit adverse binding Silence or knockdown RNA to prevent protein expression Replace proteins and enzymes Inhibit protein signaling pathways Degrade disease-causing proteins GOAL APPROACH September 2025 16 Entrada’s flexible approach to intracellular therapeutics enables pipeline expansion by leveraging new moieties and by targeting additional therapeutic areas PROTEINSRNA TARGET DNA
Page 17
Multiple near and long-term value drivers Cash runway into Q2 2027 September 2025 17 • ENTR-601-44: Multiple clinical study sites activated in UK and EU; FPD with Cohort 1 data expected H1 2026; Authorized US study planned for H1 2026 • ENTR-601-45: Multiple clinical study sites activated in UK and EU; FPD expected Q3 2025 with Cohort 1 data expected mid-2026 • ENTR-601-50: Global Phase 1/2 MAD regulatory filings expected in Q4 2025 • ENTR-601-51: Global Phase 1/2 MAD regulatory filings expected in 2026 • VX-670: MAD portion of global Phase 1/2 ongoing • EEV platform is broadly applicable to intracellular targets and a wide range of diseases • Efficient development framework in place for advancing new therapeutic candidates • Next-generation EEVs demonstrate at least 4x improvement in therapeutic index • Preclinical data support potential for broad therapeutic index across multiple diseases • Initial focus on additional neuromuscular, ocular and metabolic diseases Pipeline ExpansionFour clinical-stage programs expected in 2025
Page 18
Appendix: Additional preclinical data
Page 19
Distribution to satellite cells provides a basis for the rapid and durable efficacy generated by PMO-EEVs 19September 2025 • RNA-ISH data confirms that EEV-PMO is co-localized in 100% of satellite cells at 48 hours • IHC data demonstrates co-localization in hDMD mice ▪ Satellite cells at 7 days ▪ Satellite cells and newly regenerated centrally nucleated fibers 12 weeks post-washout after 3 Q6W doses • Creates a pool of treated stem cells to potentially improve patient’s regenerative capacity across a range of musculoskeletal disease PMO co-localizes with satellite cells and newly regenerated centrally nucleated fibers 12 weeks post- washout; A pool of stem cells to enhance regenerative capacity and treatment response durability D2-mdx mice were treated with 3 IV doses of EEV-PMO administered every six weeks; Gastrocnemius was collected 12 weeks after the third dose and analyzed by immunohistochemistry; Q6W: Every six weeks.
Page 20
Consistent and durable efficacy across species Untreated 3 μM 1 μM 0.3 μM 0.1 μM 0.03 μM 0 20 40 60 80 100 ~40-fold higher ENTR-601-44 Exon 44 Skipping in Healthy and Patient Myoblasts Exon 44 Skipping (%) Healthy cells; n=4 cells/dose Patient cells (DMDΔ45); n=4 cells/dose Exon 44 Skipping (%) Week 1 Week 2 Week 4 Week 8 Week 12 0 20 40 60 80 100 Exon 44 Skipping in hDMD Mouse • Post-IV infusion of single 35 mg/kg (PMO equivalent) dose, robust exon 44 skipping observed in biceps in the ENTR- 601-44 treated NHPs (n=3 per cohort) for at least 12 weeks Pre dose Day 2 Day 7 Day 14 Day 19 Day 28 Day 35 Day 42 Day 56 Day 70 Day 84 0 20 40 60 80 100 • Single 60 mg/kg (PMO equivalent) dose • Tibialis anterior Exon 44 Skipping in NHP September 2025 20 Cohort 1 Cohort 2 Exon 44 Skipping (%) ENTR-601-44 Significant potential for patient benefit is supported by ENTR-601-44 data in the mouse and the NHP at clinically relevant levels; in vitro data suggest much higher target engagement in patient cells Data presented at the 2022 MDA Clinical and Scientific Conference, TIDES 2022 and OPT 2024.
Page 21
Dose-dependent exon skipping and dystrophin • Del45hDMD.mdx mice dosed with EEV-PMO-44*** • n=4, gastrocnemius sample collection 2 weeks post-injection Dystrophin Restoration** 15 mg/kg 30 mg/kg 60 mg/kg 0 20 40 60 80 100% Dystrophin Restoration Dose Exon Skipping* 15 mg/kg 30 mg/kg 60 mg/kg 0 20 40 60 80 100 Dose % Exon 44 Skipping Dose-dependent response at a minimally effective dose of 15 mg/kg is observed, with near saturation at a clinically relevant dose of 60 mg/kg implying a wide therapeutic index September 2025 21*ddPCR: Double drop PCR; **JESS: Automated western blot system; ***EEV conjugated to an exon 44 skipping PMO; Data on file. ENTR-601-44
Page 22
Preclinical data support potential for best-in-class clinical profile for ENTR-601-45 Data are shown as mean ± SD; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001; 25 mg/kg correlates to ~5 mg/kg human equivalent dose (HED), 50 mg/kg correlates to ~10 mg/kg HED, 75 mg/kg correlates to ~15 mg/kg HED; Data presented at the 2024 World Muscle Society conference. • Active and vehicle del44hDMD.mdx mice, n=5 per cohort, EEV-PMO-45 (Q6W x 3 doses); Control saline treated hDMD.mdx mice, n=10 (Q6W x 3 doses) • Skipping (ddPCR) and dystrophin production (JESS) is significantly increased 6 weeks after the third dose of ENTR-601-45 (gastrocnemius muscle shown) Dystrophin RestorationExon Skipping Functional Correction Dose-dependent increase in exon skipping and dystrophin expression correlates to functional correction to wild type September 2025 22 ENTR-601-45 0 20 40 60 80 100% Human Exon 45 Skipping ** **** **** Dose in mg/kg 0 20 40 60 80 100 Dystrophin Restoration (%) Normalized to hDMD.mdx **** *** Dose in mg/kg 0 20 40 60 80 100% Dystrophin Positive Fibers **** **** **** Dose in mg/kg 0 50 100% Force After 10 Contractions **** **** **** *** Dose in mg/kg
Page 23
Dose-dependent and durable improvements in muscle function observed in del44hDMD.mdx mice September 2025 23 Skeletal Muscle Membrane Stability Stability After Washout del44hDMD.mdx mice were treated with three Q6W IV injections of ENTR-601-45 or vehicle; ECC-induced muscle force loss generated by repeated eccentric force (ECC) contraction of the gastrocnemius muscle was assessed 5 weeks (left/center) or 4 and 8 weeks (right) after the third dose; Data (mean ± standard deviation) shown across 10 ECC contractions normalized into a percentage of the initial force before any ECC contractions and as the percentage of force retained after the tenth contraction; Vehicle-treated hDMD.mdx mice were used as a control group for normal muscle function; One-way ANOVA was used for statistical comparison to vehicle-treated del44hDMD.mdx mice; Q6W: every 6 weeks; **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. vehicle; Data presented at the 2024 World Muscle Society conference. ENTR-601-45 Dose-dependent increase in resistance to membrane damage was observed following the tenth contraction, which was maintained until at least 8 weeks after the third Q6W dose of ENTR-601-45
Page 24
ENTR-601-50 in hDMD show high levels of durable exon skipping • Repeated doses administered via IV injection (Q6W x 3 doses) with 1 or 6 -week washout; Exon skipping assessed by ddPCR (tibialis anterior muscle shown) Data are shown as mean ± SD; **p ≤ 0.01, ****p ≤ 0.0001 vs vehicle; Data on file.September 2025 24 ENTR-601-50 Repeated doses of ENTR-601-50 in hDMD mice leads to robust dose-responsive levels of exon 50 skipping that largely persists to 6 weeks, supporting the potential for persistent dystrophin production hDMD mouse 1 Week after Last Dose hDMD mouse 6 Weeks after Last Dose ENTR-601-50 Vehicle Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 0 20 40 60 80 100 % Exon 50 Skipping **** **** **** ** ENTR-601-50 Vehicle Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 0 20 40 60 80 100 % Exon 50 Skipping **** **** **
Page 25
Learn more at EntradaTx.com